Revolution Medicines' RASONQUE Shows Promising Results in NSCLC Phase 1/2 Trial — Revolution Medicines, Inc.

Event summary

Phase 1/2 trial data for RASONQUE (daraxonrasib) in metastatic non-small cell lung cancer (NSCLC) published in NEJM on September 2, 2026.
Trial showed 42% objective response rate and 89% disease control rate in docetaxel-naïve patients.
Median progression-free survival was 8.3 months and median overall survival was 16.0 months.
RASONQUE demonstrated manageable safety profile with 25% Grade 3 treatment-related adverse events.

The big picture

Revolution Medicines' RASONQUE targets a significant unmet need in NSCLC, where RAS mutations are prevalent but lack targeted therapies. The positive Phase 1/2 data supports the ongoing Phase 3 trial and reinforces the company's strategy of leveraging its RAS(ON) platform across multiple cancer indications. The recent FDA approval in pancreatic cancer further validates the approach, positioning Revolution Medicines as a key player in the RAS-targeted oncology space.

What we're watching

Clinical Validation: Whether the Phase 1/2 results will translate into successful outcomes in the ongoing Phase 3 RASolve 301 trial.
Regulatory Pathway: The pace at which Revolution Medicines can secure FDA approval for RASONQUE in NSCLC following the recent approval in pancreatic cancer.
Market Positioning: How Revolution Medicines will position RASONQUE against existing therapies for RAS mutant NSCLC.